Caribou Biosciences (CRBU) Operating Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Operating Expenses data on file, last reported at $28.7 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $28.7 million, down 36.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $142.9 million (down 17.6% YoY), and the FY2025 annual result was $159.5 million, down 9.69% from the prior year.
• Operating Expenses fell to $28.7 million in Q1 2026 per CRBU's latest filing, from $32.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $50.2 million in Q2 2025 and troughed at $23.5 million in Q1 2022.
• A 5-year average of $37.4 million and a median of $36.6 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses jumped 87.06% in 2022, then slumped 36.65% in 2026.
• A 5-year view of Operating Expenses shows it stood at $34.3 million in 2022, then rose by 19.64% to $41.0 million in 2023, then retreated by 0.12% to $41.0 million in 2024, then slipped by 20.9% to $32.4 million in 2025, then declined by 11.47% to $28.7 million in 2026.
• Business Quant data shows CRBU's Operating Expenses at $28.7 million in Q1 2026, $32.4 million in Q4 2025, and $31.6 million in Q3 2025.